Upstream / Downstream

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Product Includes Quantity Applications Reactivity MW(kDa) Isotype
E-Cadherin (24E10) Rabbit mAb 3195 x 40 µl
H M 135 Rabbit IgG
p53 (7F5) Rabbit mAb 2527 1 x 40 µl
H Mk 53 Rabbit IgG
Stathmin Antibody 3352 1 x 40 µl
H M R Mk 19 Rabbit 
BRCA1 Antibody 9010 1 x 40 µl
H 220 Rabbit 
Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb 4060 1 x 40 µl
H M R Hm Mk Dm Z B 60 Rabbit IgG
PTEN (138G6) Rabbit mAb 9559 1 x 40 µl
H M R Mk 54 Rabbit IgG
Phospho-Estrogen Receptor α (Ser167) (D1A3) Rabbit mAb 5587 1 x 40 µl
H 66 Rabbit IgG
HER2/ErbB2 (D8F12) XP® Rabbit mAb 4290 1 x 40 µl
H 185 Rabbit IgG
Anti-rabbit IgG, HRP-linked Antibody 7074 1 x 100 µl
All Goat 

Product Description

The Oncogenes and Tumor Suppressor Antibody Sampler Kit offers an economical means of investigating proteins commonly involved in the biological pathways behind oncogenesis, tumor metastasis, and cancer pathology. The kit contains enough primary and secondary antibody to perform four western blot experiments with each antibody.


Specificity / Sensitivity

Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb recognizes endogenous levels of Akt only when phosphorylated at Ser473. BRCA1 Antibody recognizes endogenous levels of total BRCA1 protein. The antibody detects BRAC1 nuclear isoforms 1, 2, and 4, but not BRAC1 cytoplasmic isoforms 3 and 5, and does not detect BRCA2. E-Cadherin (24E10) Rabbit mAb recognizes endogenous levels of total E-cadherin protein. The antibody does not cross-react with related family members, such as N-cadherin. Phospho-Estrogen Receptor α (Ser167) (D1A3) Rabbit mAb recognizes endogeneous levels of ERα only when phosphorylated at Ser167. The antibody cross reacts with a nonspecific band at around 77 kDa. HER2/ErbB2 (D8F12) XP® Rabbit mAb recognizes endogenous levels of total HER2/ErbB2 protein. p53 (7F5) Rabbit mAb detects endogenous levels of total p53 protein. The antibody binding has been mapped to the amino terminus region of human p53 protein. PTEN (138G6) Rabbit mAb recognizes endogenous levels of total PTEN protein. Stathmin Antibody recognizes endogenous levels of total stathmin protein. The antibody does not cross-react with related proteins, such as SCG10, SCLIP, and RB3.


Source / Purification

Phospho-specific monoclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Ser473 of human Akt protein or Ser167 of human estrogen receptor α protein. Monoclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro780 of human E-cadherin protein, residues near the amino terminus of human HER2/ErbB2 protein, the carboxy terminus of human PTEN protein, or with a full-length human p53 fusion protein. Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding the amino terminus of human BRCA1 protein or residues surrounding Ser38 of human stathmin protein. Polyclonal antibodies are purified by protein A and peptide affinity chromatography.

Oncogenesis is a multistep process leading to sequential alterations in several oncogenes, tumor-suppressor genes, and microRNA genes (1,2). These alterations often disrupt the expression, function, and/or activity of proteins regulating cell growth and programmed cell death. Many of the molecular mechanisms and biological pathways driving oncogenesis and cancer pathology have been identified. The signal transduction pathways regulating apoptosis, cell-cycle progression, cell adhesion, cell migration, and DNA damage responses are often disrupted. HER2/ErbB2 (3), E-Cadherin (4), p53 (5,6), Stathmin (7), BRCA1 (8,9), Akt (10), PTEN (11), and Estrogen Receptor α (12) function in many of these pathways.


1.  Berger, A.H. et al. (2011) Nature 476, 163-9.

2.  Saal, L.H. et al. (2008) Nat Genet 40, 102-7.

3.  Peltomäki, P. (2012) Exp Cell Res 318, 299-310.

4.  Dittadi, R. and Gion, M. (2000) J Natl Cancer Inst 92, 1443-4.

5.  Hazan, R.B. et al. (2004) Ann N Y Acad Sci 1014, 155-63.

6.  Rahman, N. and Stratton, M.R. (1998) Annu Rev Genet 32, 95-121.

7.  Freed-Pastor, W.A. and Prives, C. (2012) Genes Dev 26, 1268-86.

8.  Belletti, B. and Baldassarre, G. (2011) Expert Opin Ther Targets 15, 1249-66.

9.  Gayther, S.A. et al. (1999) Am J Hum Genet 65, 1021-9.

10.  Scully, R. and Livingston, D.M. (2000) Nature 408, 429-32.

11.  Jazirehi, A.R. et al. (2012) Am J Cancer Res 2, 178-91.

12.  Pópulo, H. et al. (2012) Int J Mol Sci 13, 1886-918.


Entrez-Gene Id 207, 208, 10000, 672, 2099, 999, 2064, 5728, 7157, 3925
Swiss-Prot Acc. P31749, P31751, Q9Y243, P38398, P03372, P12830, P04626, P60484, P04637, P16949

Protein Specific References

Germack R and Dickenson JM (2000) Br J Pharmacol 130, 867–74

Wick MJ et al. (2000) J Biol Chem 275, 40400–6

Rane MJ et al. (2001) J Biol Chem 276, 3517–23

Guizzetti M and Costa LG (2001) Neuroreport 12, 1639–42

Brognard J et al. (2001) Cancer Res 61, 3986–97

Maira SM et al. (2001) Science 294, 374–80

Schönherr E et al. (2001) J Biol Chem 276, 40687–92

Hill MM et al. (2001) J Biol Chem 276, 25643–6

Dhawan P et al. (2002) Cancer Res 62, 7335–42

Conus NM et al. (2002) J Biol Chem 277, 38021–8

Sano H et al. (2002) J Biol Chem 277, 19439–47

Egawa K et al. (2002) J Biol Chem 277, 38863–9

Kisseleva MV et al. (2002) J Biol Chem 277, 6266–72

Barry FA and Gibbins JM (2002) J Biol Chem 277, 12874–8

Ikonomov OC et al. (2002) Endocrinology 143, 4742–54

Rani MR et al. (2002) J Biol Chem 277, 38456–61

Ho R et al. (2002) Cancer Res 62, 6462–6

Wan X and Helman LJ (2003) Oncogene 22, 8205–11

Fukuda T et al. (2003) J Biol Chem 278, 51324–33

Kim HH et al. (2003) FASEB J 17, 2163–5

Min YH et al. (2004) Cancer Res 64, 5225–31

Tazzari PL et al. (2004) Br J Haematol 126, 675–81

Matsuzaki H et al. (2004) Biochemistry 43, 4284–93

Wolfrum S et al. (2004) Arterioscler Thromb Vasc Biol 24, 1842–7

Kaneko Y et al. (2004) J Cell Sci 117, 407–15

Esfandiarei M et al. (2004) J Virol 78, 4289–98

Baudhuin LM et al. (2004) FASEB J 18, 341–3

Dietze EC et al. (2004) Oncogene 23, 3851–62

Wu T et al. (2004) Mol Cancer Ther 3, 299–307

Honjo S et al. (2005) DNA Cell Biol 24, 141–7

Karlsson HK et al. (2005) Diabetes 54, 1459–67

Viniegra JG et al. (2005) J Biol Chem 280, 4029–36

Le XF et al. (2005) J Biol Chem 280, 2092–104

Smith E and Frenkel B (2005) J Biol Chem 280, 2388–94

Edwards LA et al. (2005) Oncogene 24, 3596–605

Karlsson HK et al. (2005) Diabetes 54, 1692–7

Kippenberger S et al. (2005) J Biol Chem 280, 3060–7

Jung HS et al. (2005) Mol Endocrinol 19, 2748–59

Khundmiri SJ et al. (2006) Am J Physiol Cell Physiol 291, C1247–57

Hers I and (2007) Blood 110, 4243–52

Ananthanarayanan B et al. (2007) J Biol Chem 282, 36634–41

Zunder ER et al. (2008) Cancer Cell 14, 180–92

Grenegård M et al. (2008) J Biol Chem 283, 18493–504

Abubaker J et al. (2009) Mol Cancer 8, 51

Chen PL and Easton AS (2011) Curr Neurovasc Res 8, 14–24

Van Aller GS et al. (2011) Biochem Biophys Res Commun 406, 194–9

Uesugi A et al. (2011) Cancer Res 71, 5765–78

Ou YH et al. (2011) Mol Cell 41, 458–70

Wang S et al. (2012) PLoS One 7, e37427

Glidden EJ et al. (2012) J Biol Chem 287, 581–8

Shih MC et al. (2012) Oncogene 31, 2389–400

Misra UK and Pizzo SV (2012) J Cell Biochem 113, 1488–500

Johnson AL et al. (2001) Biol Reprod 64, 1566–74

Zhang M and Riedel H (2009) J Cell Biochem 107, 65–75

Métivier R et al. (2002) EMBO J 21, 3443–53

Dutertre M and Smith CL (2003) Mol Endocrinol 17, 1296–314

Lu Q et al. (2003) J Biol Chem 278, 4639–45

Cui Y et al. (2004) Cancer Res 64, 9199–208

Murphy L et al. (2004) Clin Cancer Res 10, 1354–9

Murphy LC et al. (2004) Clin Cancer Res 10, 5902–6

Staka CM et al. (2005) Endocr Relat Cancer 12 Suppl 1, S85–97

Chen J et al. (2005) Blood 106, 328–37

Medunjanin S et al. (2005) J Biol Chem 280, 33006–14

Yamashita H et al. (2005) Breast Cancer Res 7, R753–64

Gburcik V et al. (2005) Mol Cell Biol 25, 3421–30

Shah YM and Rowan BG (2005) Mol Endocrinol 19, 732–48

Kim MY et al. (2006) Mol Endocrinol 20, 1479–93

Kuske B et al. (2006) Endocr Relat Cancer 13, 1121–33

Sekine Y et al. (2007) Oncogene 26, 6038–49

Britton DJ et al. (2008) J Am Soc Mass Spectrom 19, 729–40

Thomas RS et al. (2008) J Mol Endocrinol 40, 173–84

Kok M et al. (2009) J Natl Cancer Inst 101, 1725–9

He X et al. (2010) Oncogene 29, 2238–51

Ma Y et al. (2010) Mol Endocrinol 24, 76–90

Cañas A et al. (2012) Breast Cancer Res 14, R153

Bhatt S et al. (2012) Mol Cell Biol 32, 1928–43

Chen, D. et al. (2000) Mol Cell 6, 127-37.

Dankort D et al. (2001) Mol Cell Biol 21, 1540–51

Ren Z and Schaefer TS (2002) J Biol Chem 277, 38486–93

Marone R et al. (2004) Nat Cell Biol 6, 515–22

Montgomery RB et al. (2005) Cancer Res 65, 650–6

Bose R et al. (2006) Proc Natl Acad Sci U S A 103, 9773–8

Xu W et al. (2007) Mol Cell Biol 27, 220–8

Northey JJ et al. (2008) Mol Cell Biol 28, 3162–76

Frogne T et al. (2009) Breast Cancer Res 11, R11

Al-Khouri AM et al. (2005) J Biol Chem 280, 35195–202

Okumura K et al. (2006) J Biol Chem 281, 26562–8

Ikenoue T et al. (2008) Cancer Res 68, 6908–12

Maddika S et al. (2011) Nat Cell Biol 13, 728–33

Zhang XC et al. (2012) Biochem J 444, 457–64

González-Santamaría J et al. (2012) Cell Death Dis 3, e393

Putz U et al. (2012) Sci Signal 5, ra70

Bassi C et al. (2013) Science 341, 395–9

Kavela S et al. (2013) Cancer Res 73, 205–14

Chehab NH et al. (1999) Proc Natl Acad Sci U S A 96, 13777–82

Buschmann T et al. (2000) Cancer Res 60, 896–900

Chehab NH et al. (2000) Genes Dev 14, 278–88

Persons DL et al. (2000) J Biol Chem 275, 35778–85

Vaziri H et al. (2001) Cell 107, 149–59

Minamoto T et al. (2001) Oncogene 20, 3341–7

Stewart ZA et al. (2001) Oncogene 20, 113–24

Bean LJ and Stark GR (2001) Oncogene 20, 1076–84

Xie S et al. (2001) J Biol Chem 276, 43305–12

Xie S et al. (2001) J Biol Chem 276, 36194–9

Kim SJ et al. (2002) J Biol Chem 277, 33501–8

Bulavin DV et al. (2002) Nat Genet 31, 210–5

Shono T et al. (2002) Cancer Res 62, 1069–76

Adamson AW et al. (2002) J Biol Chem 277, 38222–9

Hase H et al. (2002) J Biol Chem 277, 46950–8

Bischof O et al. (2002) EMBO J 21, 3358–69

Qin JZ et al. (2002) Oncogene 21, 2991–3002

Hofmann TG et al. (2002) Nat Cell Biol 4, 1–10

Chouinard N et al. (2002) Biochem J 365, 133–45

Shiseki M et al. (2003) Cancer Res 63, 2373–8

Chen K et al. (2003) J Biol Chem 278, 39527–33

Sengupta S et al. (2003) EMBO J 22, 1210–22

Urban G et al. (2003) J Biol Chem 278, 9747–53

Oguchi K et al. (2003) Blood 101, 3622–7

Hideshima T et al. (2003) Blood 101, 1530–4

Lindström MS and Wiman KG (2003) Oncogene 22, 4993–5005

Hofseth LJ et al. (2003) Proc Natl Acad Sci U S A 100, 143–8

Wang C and Chen J (2003) J Biol Chem 278, 2066–71

Matsuoka M et al. (2003) Environ Health Perspect 111, 509–12

Yanamadala S and Ljungman M (2003) Mol Cancer Res 1, 747–54

Möller A et al. (2003) Cancer Res 63, 4310–4

Goudelock DM et al. (2003) J Biol Chem 278, 29940–7

Louria-Hayon I et al. (2003) J Biol Chem 278, 33134–41

Tritarelli A et al. (2004) Mol Biol Cell 15, 3751–7

Mroz RM et al. (2004) Am J Respir Cell Mol Biol 30, 564–8

Rui Y et al. (2004) EMBO J 23, 4583–94

Li Y et al. (2004) Oncogene 23, 7355–65

Vaghefi H and Neet KE (2004) Oncogene 23, 8078–87

Nair VD et al. (2004) J Biol Chem 279, 27494–501

Takagi M et al. (2004) Blood 103, 283–90

Ito K et al. (2004) Cancer Res 64, 1071–8

Koutsodontis G and Kardassis D (2004) Oncogene 23, 9190–200

Jackson MW et al. (2004) Oncogene 23, 4477–87

Dohoney KM et al. (2004) Oncogene 23, 49–57

Thompson T et al. (2004) J Biol Chem 279, 53015–22

Yeh PY et al. (2004) Oncogene 23, 3580–8

Komiyama S et al. (2004) Biochem Biophys Res Commun 323, 816–22

Soubeyrand S et al. (2004) Eur J Biochem 271, 3776–84

Ou YH et al. (2005) Mol Biol Cell 16, 1684–95

Feki A et al. (2005) Oncogene 24, 3726–36

Li Z et al. (2005) J Biol Chem 280, 16843–50

Di Stefano V et al. (2005) Oncogene 24, 5431–42

Hershko T et al. (2005) Cell Death Differ 12, 377–83

Mayo LD et al. (2005) J Biol Chem 280, 25953–9

Wesierska-Gadek J et al. (2005) Mol Cancer Ther 4, 113–24

Wang L et al. (2005) Oncogene 24, 3020–7

Zhao Y et al. (2006) Mol Cell Biol 26, 2782–90

Gresko E et al. (2006) EMBO J 25, 1883–94

Ichwan SJ et al. (2006) Oncogene 25, 1216–24

Knights CD et al. (2006) J Cell Biol 173, 533–44

Moiseeva O et al. (2006) Mol Biol Cell 17, 1583–92

Zeng PY and Berger SL (2006) Cancer Res 66, 10701–8

Li AG et al. (2006) Mol Cell 23, 575–87

Yoshida K et al. (2006) J Biol Chem 281, 5734–40

Li DW et al. (2006) Oncogene 25, 3006–22

Fraser M et al. (2006) Oncogene 25, 2203–12

Paulsen MT et al. (2006) Mol Cancer 5, 25

Singh K et al. (2007) PLoS One 2, e660

Nag A et al. (2007) J Biol Chem 282, 8812–20

Li HH et al. (2007) EMBO J 26, 402–11

Li Q et al. (2007) Cancer Res 67, 66–74

Taira N et al. (2007) Mol Cell 25, 725–38

Lambrot R et al. (2007) J Clin Endocrinol Metab 92, 2632–9

Ivanov GS et al. (2007) Mol Cell Biol 27, 6756–69

Nakanishi M et al. (2007) J Biol Chem 282, 22993–3004

Liu Y et al. (2007) J Biol Chem 282, 2505–11

Derheimer FA et al. (2007) Proc Natl Acad Sci U S A 104, 12778–83

Lee JH et al. (2007) J Cell Sci 120, 2259–71

Mantovani F et al. (2007) Nat Struct Mol Biol 14, 912–20

Wang H et al. (2008) J Biol Chem 283, 2564–74

Sun L et al. (2008) J Exp Clin Cancer Res 27, 35

Chang PC and Li M (2008) J Virol 82, 278–90

Lin T et al. (2008) Toxicology 247, 145–53

Chen JJ et al. (2008) J Immunol 180, 8030–9

Shouse GP et al. (2008) Mol Cell Biol 28, 448–56

Kitagawa M et al. (2008) Mol Cell 29, 217–31

Habold C et al. (2008) J Cell Mol Med 12, 607–21

Zhu H et al. (2008) Int J Cancer 123, 2741–9

Yamaguchi H et al. (2009) J Biol Chem 284, 11171–83

Wang Z et al. (2009) Pharm Res 26, 1140–8

Bar JK et al. (2009) Int J Gynecol Cancer 19, 1322–8

Nishimura T et al. (2009) J Biol Chem 284, 36442–52

Puca R et al. (2009) Mol Cancer 8, 85

Yadavilli S et al. (2009) J Biochem Mol Toxicol 23, 373–86

Baxter EW and Milner J (2010) J Neurooncol 97, 373–82

Fraser JA et al. (2010) J Biol Chem 285, 37773–86

Fraser JA et al. (2010) J Biol Chem 285, 37762–72

Shang X et al. (2010) Oncogene 29, 4938–46

Chen X et al. (2010) J Biol Chem 285, 12823–30

Kawano T et al. (2010) Int J Oncol 37, 787–95

Moehlenbrink J et al. (2010) Cancer Lett 292, 119–24

Venerando A et al. (2010) Cell Mol Life Sci 67, 1105–18

Puca R et al. (2010) Free Radic Biol Med 48, 1338–46

Marchenko ND et al. (2010) Cell Death Differ 17, 255–67

Aranha MM et al. (2011) PLoS One 6, e21396

Muñoz-Fontela C et al. (2011) Cell Cycle 10, 3701–5

Wu L et al. (2011) J Biol Chem 286, 2236–44

Ozeki C et al. (2011) J Biol Chem 286, 18251–60

Mellert HS et al. (2011) J Biol Chem 286, 4264–70

Valbuena A et al. (2011) PLoS One 6, e17320

Xu S et al. (2011) J Cardiovasc Pharmacol 58, 263–71

Seo SK et al. (2011) J Thorac Oncol 6, 1313–9

Savelyeva I and Dobbelstein M (2011) Oncogene 30, 865–75

Wu ZZ et al. (2011) J Cell Physiol 226, 2415–28

Smeenk L et al. (2011) PLoS One 6, e17574

Grison A et al. (2011) Proc Natl Acad Sci U S A 108, 17979–84

Gully CP et al. (2012) Proc Natl Acad Sci U S A 109, E1513–22

Wang H et al. (2012) DNA Repair (Amst) 11, 146–56

Xu S et al. (2013) Cell Res 23, 423–35

Chan C et al. (2013) Mol Cell Biol 33, 485–97

Thakur BK et al. (2013) Int J Cancer 132, 766–74

Yang Y et al. (2013) J Biol Chem 288, 529–39

Parker CG et al. (1998) Biochem Biophys Res Commun 249, 791–6

Takahashi K and Suzuki K (2009) Cell Signal 21, 695–703


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
U.S. Patent No. 5,675,063.